ScotW.EbbinghausMD

Hematologic Oncology

Physician

Dr. Ebbinghaus is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
333 Cottman Avenue
Fox Chase Cancer Cenetr
Philadelphia, PA 19111
Phone+1 215-728-6900

Fax+1 215-728-3639

University of Alabama Medical CenterFellowship, Hematology and Medical Oncology, 1993 - 1996
University of Alabama Medical CenterResidency, Internal Medicine, 1989 - 1993
University of Missouri Kansas City School of MedicineClass of 1989

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Study Evaluating the Safety and Tolerability of L-377202 Start of enrollment: 1999 Mar 01
Completed
Phase 1, Phase 2

PubMed

Outcomes by Line of Therapy and Programmed Death Ligand 1 Expression in Patients with Advanced Melanoma Treated with Pembrolizumab or Ipilimumab in KEYNOTE-006: A Randomised Clinical TrialAugust 2018

USFDA Grants Breakthrough Therapy Designation to Sacituzumab Tirumotecan for Metastatic Nonsquamous Non Small Cell Lung Cancer with EGFR Mutations: MerckDecember 3rd, 2024
USFDA Accepts Application for Merck KEYTRUDA plus Chemotherapy as First Line Treatment for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaApril 13th, 2023
Merck Keytruda Gets Full USFDA Approval for Advanced MSI-H or dMMR Solid TumorsApril 1st, 2023
Join now to see all

Site Specific Alkylation Of The Her2/Neu PromoterNational Cancer Institute2002–2004
Specific Inhibition Of Her2/Neu Transcription ElongationNational Cancer Institute2000–2002
Specific Inhibition Of Her2/Neu Transcription ElongationNational Cancer Institute1998–2000
Triplex Based Gene Therapy Of Breast And Ovarian CancerNational Cancer Institute1996–1998